Aurobindo Pharma Ltd

Aurobindo Pharma | 524804

Market Closed

₹1,232.50

+₹0.00 (+-0.55%)

As on 19/11/25, 9:53 AM

Market Cap72,615.37 CR

Current Price₹1,232.5

High / Low₹1,356.2 / 1,010

PE Ratio19.32

Book Value₹562.21

Dividend Yield0.00%

ROCE14.16%

ROE8.68%

Face Value₹2.00

Current Vol.48,558

Average Vol.12,76,53,456

ISININE406A01037

PB Ratio2.06

Debt to Equity0.24

Net Profit Margin10.98

Operating Margin22.61

Stock cgart

Stock Performance

₹2,480₹2,490

₹2,500

Previous CloseToday's Open

₹1,800₹3,000

₹2,500

52W Low52W High

₹2,480Today's Open

₹2,490Previous Close

12,00,000Volume

₹1,80052W Low

₹3,00052W High

Ratios

No data available

About Company

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company
Nityananda Reddy and a small, highly committed group of professionals founded it
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities
Aurobindo Pharma has identified international operations also catering to over 150 countries
The Company has accelerated the DMF/ANDA filings programme in its efforts to build a broad product portfolio for the regulated markets
Cumulatively, the Company has filed a total of 337 DMFs (Drug Master Files), of which 110 are with US FDA, and 133 in Europe including with the EDQM and 102 in other countries
This is one of the highest filings
The Company commenced its operations during the year 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry and it became a public venture in 1992

Research Calls

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

;

Technical Indicators

RSI75.53

SMA 201145.94

SMA 501115.60

SMA 1001108.70

SMA 2001131.63

SMA 101182.90

MACD_12_26_Days32.71

EMA10Day1192.32

EMA20Day1162.65

EMA50Day1129.57

MACD_12_26_9_Days11.03

EMA100Day1125.14

EMA200Day1142.68

Pivot Points

Volume Analysis

Growth Rate

Revenue Growth9.39%

ROE11.15%

EBITDA Margin22.61%

All figures in ₹ Crores

Indicators	2025	2024	2023	2022	2021
Revenue	31,723.73	29,001.87	24,855.38	23,455.49	24,774.62
Interest	457.24	289.71	140.48	48.64	74.49
Expenses	25,172.63	23,176.03	21,148.41	19,099.97	19,496.58
Financing Profit	7,172.95	6,383.22	3,997.56	4,675.87	5,658.89
Financing Margin %	23%	22%	16%	20%	23%
Other Income	621.85	557.38	290.59	320.35	380.85
Depreciation	1,649.42	1,521.66	1,244.58	1,126.52	1,055.39
Profit before tax	5,066.29	4,379.99	2,612.50	3,372.74	7,343.59
Tax %	31%	28%	26%	22%	27%
Net Profit	3,483.57	3,168.97	1,927.65	2,647.11	5,333.82
EPS in Rs	59.81	54.16	32.90	45.20	91.05

Show % Change

ShareHolding

📊

No Information Available

No shareholding data available at this time.

Deal	Date	Type	Quantity	Price	Traded %
GOLDMAN SACHS BANK EUROPESE - ODI	16 Oct ‘25	Purchase	1,06,228	₹1,107	6.21%
GOLDMAN SACHS (SINGAPORE) PTE.- ODI	16 Oct ‘25	Sell	1,06,228	₹1,107	6.21%
MARSHALL WACE INVESTMENT STRATEGIES SYSTEMATIC ALPHA PLUS FUND	25 Jan ‘24	Purchase	862	₹1,160.1	0.04%
MARSHALL WACE INVESTMENT STRATEGIES EUREKA FUND	25 Jan ‘24	Purchase	53,641	₹1,160.1	2.75%
MARSHALL WACE INVESTMENT STRATEGIES MARKET NEUTRAL TOPS FUND	25 Jan ‘24	Purchase	8,134	₹1,160.1	0.42%
MARSHALL WACE INVESTMENT STRATEGIES TOPS FUND	25 Jan ‘24	Purchase	44,921	₹1,160.1	2.30%
SOCIETE GENERALE	25 Jan ‘24	Sell	1,07,558	₹1,160.1	5.51%
ISHARES CORE MSCI EMERGING MARKETS ETF	14 Nov ‘22	Purchase	2,97,308	₹489.3	3.21%
ISHARES CORE EMERGING MARKETS MAURITIUS CO	14 Nov ‘22	Sell	2,97,308	₹489.3	3.21%
ISHARES CORE MSCI EMERGING MARKETS ETF	03 Nov ‘22	Purchase	2,97,309	₹557.3	52.41%

News

14 Nov 2025 12:00 am

USFDA issues EIR for Unit 1 of Apitoria Pharma

14 Nov 2025 12:00 am

Aurobindo Pharma Ltd soars 0.71%, gains for fifth straight session

Record Date

Corporate Action

Information

Announcement Day

10 Sept 2025

AGM

12 Aug 2025

08 Aug 2025

Interim Dividend (₹4)

The Board of Directors of the company at its meeting held today August 4, 2025, has approved the payment of Interim Dividend of 400% i.e Rs.4.00 (Rupees Four Only) per equity share of Rs.1. /- each on equity share capital of the company, The Company has fixed August 8, 2025 as the record date for purpose of the payment of interim Dividend and the same will paid on or before August 21, 2025.

04 Aug 2025

29 Aug 2024

AGM

30 Jul 2024

05 Aug 2024

Buyback

Tender Offer - Max Price: ₹1460, Amount: ₹750Cr

18 Jul 2024

20 Feb 2024

Interim 2 Dividend (₹1.5)

Board of Directors in their meeting held today, February 10, 2024, approved the payment of Second Dividend of 150% i.e. Rs.1.50 per shares of Re.1 each.

10 Feb 2024

20 Nov 2023

Interim 1 Dividend (₹3)

The Board of Directors of the Company at its meeting held today, November 9, 2023, has inter alia, transacted the following items of business: Approved first interim dividend of 300% i.e., Rs.3.00 (Rupees three only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has already fixed November 20, 2023 as the record date for the purpose of payment of interim dividend for the financial year 2023-24 and the said interim dividend will be paid on or before December 4, 2023.

09 Nov 2023

25 Aug 2023

AGM

28 Jul 2023

17 Feb 2023

Interim 1 Dividend (₹3)

The Board of Directors of the Company at its meeting held today, February 9, 2023, has inter alia, transacted the following items of business: Approved first interim dividend of 300% i.e. Rs.3.00 (Rupees three only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has already fixed February 17, 2023 as the record date for the purpose of payment of interim dividend for the financial year 2022-23. The interim dividend will be paid on or before March 3, 2023.

09 Feb 2023

02 Aug 2022

AGM

07 Jul 2022

07 Jun 2022

Interim 4 Dividend (₹4.5)

The Board of Directors of the Company at its meeting held today, May 30, 2022, has inter alia, approved fourth interim dividend of 450% i.e. Rs.4.50 (Rupees four and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company. The Company has already fixed June 7, 2022 as the record date for the purpose of payment of fourth interim dividend for the financial year 2021-22. The interim dividend will be paid on or before June 15, 2022.

30 May 2022

Peers

LTP(₹)	Market Cap(₹ Cr.)	P/E Ratio(Ratio)	P/B Ratio(Ratio)	Cash Earnings(Ratio)	Debt to Equity(Ratio)	Net Profit Ratio(%)
1,240	72,630	21	2	14	0	10.98%
1,760	4,22,211	37	5	30	0	20.88%
6,475	1,71,898	69	11	59	0	23.41%
3,793	1,28,372	59	15	43	1	16.60%
1,515	1,22,349	22	4	19	0	19.21%
1,244	1,03,789	18	3	14	0	17.54%
2,047	93,506	22	5	17	0	14.56%
928	93,404	19	4	15	0	19.86%
2,224	91,800	53	6	35	0	14.39%
5,711	68,288	29	5	25	0	17.09%

Showing 10 of 124 Results

#IndiaInvests

Trusted by 2.5 lac + Indians for their wealth-building needs

Invest in stocks with ease

Open your account in less than 10 mins*

By proceeding, you agree to all T&C *

Top Losers

Frequently Asked Questions

What is Share Price of Aurobindo Pharma Ltd?

The current share price of Aurobindo Pharma Ltd (Aurobindo Pharma) is ₹1232.50. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Aurobindo Pharma Ltd?

The Price-to-Earnings (P/E) ratio of Aurobindo Pharma Ltd is 1232.50. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Aurobindo Pharma Ltd?

Aurobindo Pharma Ltd has a 52-week high of ₹1356.20 and a 52-week low of ₹1010.00. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Aurobindo Pharma Ltd?

Aurobindo Pharma Ltd offers a dividend yield of 0.00%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Aurobindo Pharma Ltd?

The Earnings Per Share (EPS) of Aurobindo Pharma Ltd is ₹58.41. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Aurobindo Pharma Ltd?

Aurobindo Pharma Ltd has a Return on Equity (ROE) of 8.68%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

Ready to invest smarter?
Download the app today.

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

App Store

4.2

Discover our app's power in seconds.